Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has received a consensus recommendation of "Buy" from the fourteen analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and two have